Sessions
Cell Therapy Commercial Success, Overcoming Pitfalls and What We Have Learned from 2022
Technology Investment for Advanced Therapies: Investing in the Future
Implementing and Integrating Disruptive Technologies for Commercial Benefit
Workshop: Investment in CGT – Securing Funding for your Biotech Venture
People Behind the Cures: Recruitment, Opportunity and Diversity for the CGT Workforce
Commercializing Gene Therapies: Building Your Strategy From Translation Through to Commercial
Paying for Cures: Creative Payment, Reimbursement, Market Access Models and Defining Value in the CGT Space
Patient-Centric Development: Keeping the Patient at the Heart of Commercializing New Medicines
test
Cell Therapy Commercial Success, Overcoming Pitfalls and What We Have Learned from 2022
SPONSORED BY
11:00am Chair Introduction
Peter Olagunju, Chief Technical Officer, TCR2 Therapeutics
11:05am Presentation: Opportunities and Challenges in the Commercialization of Cellular Therapies
- What have we learned with the commercialization of cellular therapies in oncology
- What remains a challenge and what new challenges are arising
- Identifying and creating opportunities to make cellular therapies more broadly available
Cintia Piccina, Chief Commercial Officer, Adaptimmune
11:20am Presentation: A CDMO Perspective – Building cell therapy capabilities to address current and future demand
- Build or buy: What did we learn from the capital markets in 2021?
- Testing: Avoiding clinical delays through timely development
- Manufacturing: Setting up CT manufacturing to address current and future demand
- Allogeneic therapies: Where do we stand?
John Lee, Vice President, Head of Cell Therapy, Center for Breakthrough Medicines
11:35am Presentation: Industrializing CAR-T: From Autologous Launches to Allogeneic Successes
- Autologous therapies have proven the clinical potential of CAR-T, with several launches in the last few years.
- Allogeneic therapies are around the corner and will offer a true industrialized drug model for CAR-T.
- What can allogeneic therapies learn from the first years of autologous commercialization to be better positioned for success?
Arthur Stril, Chief Business Officer, Cellectis
11:50am Presentation: Accelerating Commercialization with Custom Assay Development Strategies
- Use of high-throughput qualitative Infectious Disease Monitoring assays
- Development of a series of platform potency assays
- Development of a miniaturized Dynamic Flow-Based System to mimic biological system
Scott Jones, Chief Scientific Officer, BioBridge Global
12:05pm Closing Panel with Q&A
With all session participants
Speakers
